1-11 of 11
Joseph P. McGuirk
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lisocabtagene Maraleucel for Relapsed/Refractory Large B-Cell Lymphoma: A Cell Therapy Consortium Real-World Analysis

Clinical Trials & Observations
Peter A. Riedell, Connor B. Grady, Loretta J. Nastoupil, Alejandro Luna De Abia, Nausheen Ahmed, Richard T. Maziarz, Marie Hu, Jamie Brower, Wei-Ting Hwang, Stephen J. Schuster, Andy I. Chen, Olalekan O. Oluwole, Veronika Bachanova, Joseph P. McGuirk, Miguel-Angel Perales, Michael R. Bishop, David L. Porter
Journal: Blood Advances
Blood Adv bloodadvances.2024014164.
https://doi.org/10.1182/bloodadvances.2024014164
Published: 2024
Includes: Supplemental data
Journal Articles

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel

Nausheen Ahmed, William Wesson, Forat Lutfi, David L. Porter, Veronika Bachanova, Loretta J. Nastoupil, Miguel-Angel Perales, Richard T. Maziarz, Jamie Brower, Gunjan L. Shah, Andy I. Chen, Olalekan O. Oluwole, Stephen J. Schuster, Michael R. Bishop, Joseph P. McGuirk, Peter A. Riedell
Journal: Blood Advances
Blood Adv (2024) 8 (20): 5346–5354.
https://doi.org/10.1182/bloodadvances.2023012549
Published: 2024
Includes: Supplemental data
Journal Articles

Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Clinical Trials & Observations
Michael Scordo, Jessica R. Flynn, Mithat Gonen, Sean M. Devlin, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L. Porter, Stephen J. Schuster, Veronika Bachanova, Joseph Maakaron, Richard T. Maziarz, Andy I. Chen, Loretta J. Nastoupil, Joseph P. McGuirk, Olalekan O. Oluwole, Andrew Ip, Lori A. Leslie, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (18): 5579–5585.
https://doi.org/10.1182/bloodadvances.2023010302
Published: 2023
Includes: Supplemental data
Journal Articles

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Shakthi T. Bhaskar, Vivek G. Patel, David L. Porter, Stephen J. Schuster, Loretta J. Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R. Bishop, Joseph P. McGuirk, Richard T. Maziarz, Andy I. Chen, Veronika Bachanova, Joseph E. Maakaron, Peter A. Riedell, Olalekan O. Oluwole
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4765–4772.
https://doi.org/10.1182/bloodadvances.2022008937
Published: 2023
Journal Articles

Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G. Karrison, Rachel Treitman, Manali K. Kamdar, Bradley M. Haverkos, James Godfrey, Melissa A. Babcook, Timothy J. Voorhees, Sophie Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison M. Winter, Brian T. Hill, Radhika Bansal, Jose C. Villasboas Bisneto, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A. Pophali, Asaad Trabolsi, Jonathan H. Schatz, Marie Hu, Veronika Bachanova, Michael J. Slade, Nathan Singh, Nausheen Ahmed, Joseph P. McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4528–4538.
https://doi.org/10.1182/bloodadvances.2023010016
Published: 2023
Includes: Supplemental data
Journal Articles

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Clinical Trials & Observations
Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R. Flynn, Sean M. Devlin, Jamie Brower, Veronika Bachanova, Loretta J. Nastoupil, Joseph P. McGuirk, Richard T. Maziarz, Olalekan O. Oluwole, Stephen J. Schuster, David L. Porter, Michael R. Bishop, Peter A. Riedell, Miguel-Angel Perales
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3192–3198.
https://doi.org/10.1182/bloodadvances.2022008294
Published: 2023
Includes: Supplemental data
Journal Articles

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results

Clinical Trials & Observations
Ulrich Jaeger, Nina Worel, Joseph P. McGuirk, Peter A. Riedell, Isabelle Fleury, Yan Du, Xia Han, David Pearson, Santiago Redondo, Edmund K. Waller
Journal: Blood Advances
Blood Adv (2023) 7 (11): 2283–2286.
https://doi.org/10.1182/bloodadvances.2022007779
Published: 2023
Includes: Supplemental data
Journal Articles

Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma

Clinical Trials & Observations
Ulrich Jaeger, Constantine S. Tam, Peter Borchmann, Joseph P. McGuirk, Marianne Johansen, Edmund K. Waller, Samantha Jaglowski, Charalambos Andreadis, Stephen R. Foley, Jason R. Westin, Isabelle Fleury, P. Joy Ho, Stephan Mielke, Takanori Teshima, Gilles Salles, Stephen J. Schuster, Fiona He, Richard T. Maziarz, Sebastian Mayer, Shinichi Makita, Marie J. Kersten, Monalisa Ghosh, Nina Wagner-Johnston, Koji Kato, Paolo Corradini, Hideki Goto, Silvia Colicino, Abhijit Agarwal, Chiara Lobetti-Bodoni, Michael R. Bishop
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4816–4820.
https://doi.org/10.1182/bloodadvances.2021006193
Published: 2022
Includes: Supplemental data
Journal Articles

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma

Clinical Trials & Observations
Reid W. Merryman, Robert A. Redd, Taiga Nishihori, Julio Chavez, Yago Nieto, Justin M. Darrah, Uttam Rao, Michael T. Byrne, David A. Bond, Kami J. Maddocks, Michael A. Spinner, Ranjana H. Advani, Hatcher J. Ballard, Jakub Svoboda, Anurag K. Singh, Joseph P. McGuirk, Dipenkumar Modi, Radhakrishnan Ramchandren, Jason Romancik, Jonathon B. Cohen, Matthew J. Frigault, Yi-Bin Chen, Anthony V. Serritella, Justine Kline, Stephen Ansell, Sunita Nathan, Maryam Rahimian, Robin M. Joyce, Mansi Shah, Kevin A. David, Steven Park, Anne W. Beaven, Alma Habib, Veronika Bachanova, Shazia Nakhoda, Nadia Khan, Ryan C. Lynch, Stephen D. Smith, Vincent T. Ho, Ann LaCasce, Philippe Armand, Alex F. Herrera
Journal: Blood Advances
Blood Adv (2021) 5 (6): 1648–1659.
https://doi.org/10.1182/bloodadvances.2020003556
Published: 2021
Includes: Supplemental data
Journal Articles

Myeloablative vs reduced intensity T-cell–replete haploidentical transplantation for hematologic malignancy

Scott R. Solomon, Andrew St. Martin, Nirav N. Shah, Giancarlo Fatobene, Monzr M. Al Malki, Karen K. Ballen, Asad Bashey, Nelli Bejanyan, Javier Bolaños Meade, Claudio G. Brunstein, Zachariah DeFilipp, Richard E. Champlin, Ephraim J. Fuchs, Mehdi Hamadani, Peiman Hematti, Christopher G. Kanakry, Joseph P. McGuirk, Ian K. McNiece, Stefan O. Ciurea, Marcelo C. Pasquini, Vanderson Rocha, Rizwan Romee, Sagar S. Patel, Sumithira Vasu, Edmund K. Waller, John R. Wingard, Mei-Jie Zhang, Mary Eapen
Journal: Blood Advances
Blood Adv (2019) 3 (19): 2836–2844.
https://doi.org/10.1182/bloodadvances.2019000627
Published: 2019
Journal Articles

Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion

Clinical Trials & Observations
Michael R. Bishop, Richard T. Maziarz, Edmund K. Waller, Ulrich Jäger, Jason R. Westin, Joseph P. McGuirk, Isabelle Fleury, Harald Holte, Peter Borchmann, Christopher del Corral, Ranjan Tiwari, Özlem Anak, Rakesh Awasthi, Lida Pacaud, Vadim V. Romanov, Stephen J. Schuster
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2230–2236.
https://doi.org/10.1182/bloodadvances.2019000151
Published: 2019